Sorafenib in advanced hepatocellular carcinoma.

PubWeight™: 54.30‹?› | Rank: Top 0.01% | All-Time Top 1000

🔗 View Article (PMID 18650514)

Published in N Engl J Med on July 24, 2008


Josep M Llovet1, Sergio Ricci, Vincenzo Mazzaferro, Philip Hilgard, Edward Gane, Jean-Frédéric Blanc, Andre Cosme de Oliveira, Armando Santoro, Jean-Luc Raoul, Alejandro Forner, Myron Schwartz, Camillo Porta, Stefan Zeuzem, Luigi Bolondi, Tim F Greten, Peter R Galle, Jean-François Seitz, Ivan Borbath, Dieter Häussinger, Tom Giannaris, Minghua Shan, Marius Moscovici, Dimitris Voliotis, Jordi Bruix, SHARP Investigators Study Group

Author Affiliations

1: Barcelona Clinic Liver Cancer Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Centro de Investigaciones en Red de Enfermedades Hepáticas y Digestivas Hospital Clínic Barcelona, Barcelona.

Associated clinical trials:

A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (SHARP) | NCT00105443

Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced Hcc | NCT01897610

TRC105 for Liver Cancer That Has Not Responded to Sorafenib | NCT01375569

Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis (PRODIGE 21) | NCT01357486

The Effect of Urea Cream on Sorafenib-associated Hand-Foot Skin Reaction | NCT03212625

TACE Combined With Iodine-125 Seeds Implantation for HCC | NCT03322280

Sequential TransArterial Chemoembolization and Stereotactic RadioTherapy With ImmunoTherapy for Downstaging Hepatocellular Carcinoma for Hepatectomy (START-FIT) | NCT03817736

Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus (STUHCCPVTT) | NCT04069949

Italian Study Of Validation Of Angiogenesis Polymorphisms In HCC Patients Treated With Sorafenib (INNOVATE) | NCT02786342

Adjuvant Therapies for Patients With HCC and MVI (A-TACE/S-HCC) | NCT02436902

Efficacy and Safety of Concurrent TACE and Sorafenib in Patients With HCC and Extrahepatic Metastasis (COTSOM Study) (COTSOM) | NCT02311205

Articles citing this

(truncated to the top 100)

Management of hepatocellular carcinoma: an update. Hepatology (2011) 33.57

From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med (2009) 12.92

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet (2014) 6.36

Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16

MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med (2009) 6.13

Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol (2010) 5.87

Marital status and survival in patients with cancer. J Clin Oncol (2013) 5.82

Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79

Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology (2013) 5.05

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int (2010) 5.02

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med (2013) 4.86

Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol (2009) 4.82

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol (2009) 4.54

Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol (2009) 4.17

Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03

Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol (2009) 3.43

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget (2011) 3.43

Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol (2011) 3.36

Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer (2010) 3.33

NF-κB in the liver--linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2011) 3.28

NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw (2009) 3.25

MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem (2009) 3.16

Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol (2011) 3.03

Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer (2013) 2.87

Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol (2014) 2.86

Targeted therapies for hepatocellular carcinoma. Gastroenterology (2011) 2.85

Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma. Gastroenterology (2015) 2.81

Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest (2009) 2.79

Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell (2014) 2.71

In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat Med (2014) 2.68

Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology (2011) 2.66

A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res (2010) 2.59

Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol (2010) 2.51

Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol (2009) 2.48

Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis (2010) 2.46

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42

Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology (2013) 2.42

CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res (2011) 2.39

Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol (2011) 2.39

Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology (2010) 2.35

Sorafenib in liver cancer--just the beginning. N Engl J Med (2008) 2.29

Endogenous retrotransposition activates oncogenic pathways in hepatocellular carcinoma. Cell (2013) 2.28

Targeted therapy in non-small-cell lung cancer--is it becoming a reality? Nat Rev Clin Oncol (2010) 2.26

Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J Clin Invest (2008) 2.26

Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology (2013) 2.21

Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer (2009) 2.20

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis (2009) 2.15

Factors associated with outcomes and response to therapy in patients with infiltrative hepatocellular carcinoma. Clin Gastroenterol Hepatol (2013) 2.11

Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol (2010) 2.10

HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol (2011) 2.10

Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis (2014) 2.07

Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest (2013) 2.03

Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov (2011) 2.01

MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med (2008) 1.99

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget (2012) 1.96

Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther (2008) 1.96

Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res (2009) 1.93

A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology (2009) 1.90

MicroRNAs regulate methionine adenosyltransferase 1A expression in hepatocellular carcinoma. J Clin Invest (2012) 1.86

Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med (2010) 1.86

Therapeutic cancer vaccines: are we there yet? Immunol Rev (2011) 1.86

Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. Clin Cancer Res (2011) 1.85

Epithelial-mesenchymal transition in hepatocellular carcinoma. Future Oncol (2009) 1.85

Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA (2010) 1.84

Current management strategy of hepatocellular carcinoma. World J Gastroenterol (2009) 1.79

Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer (2009) 1.78

MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology (2011) 1.77

Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. Oncologist (2012) 1.76

Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol (2009) 1.75

Validation of novel imaging methodologies for use as cancer clinical trial end-points. Eur J Cancer (2008) 1.73

Viral hepatocarcinogenesis. Oncogene (2010) 1.73

Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology (2012) 1.71

Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med (2012) 1.71

The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer. Clin Cancer Res (2014) 1.68

Cancer gene discovery in hepatocellular carcinoma. J Hepatol (2010) 1.68

Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology (2011) 1.68

Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. J Clin Oncol (2014) 1.67

Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J Thorac Oncol (2012) 1.66

Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol (2014) 1.66

IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol (2010) 1.66

A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clin Cancer Res (2012) 1.64

Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J (2009) 1.62

Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumor's proangiogenic microenvironment. Cell Mol Life Sci (2011) 1.62

Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? Oncology (2011) 1.61

Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology (2010) 1.60

Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma. Clin Gastroenterol Hepatol (2013) 1.60

Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int (2015) 1.59

Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer (2011) 1.59

A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI). Br J Cancer (2012) 1.59

Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am (2010) 1.58

Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol (2012) 1.57

First experience of hepatic radioembolization using microspheres labelled with yttrium-90 (TheraSphere): practical aspects concerning its implementation. Eur J Nucl Med Mol Imaging (2009) 1.56

Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology (2010) 1.55

Role of Wnt/β-catenin signaling in liver metabolism and cancer. Int J Biochem Cell Biol (2009) 1.55

Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget (2012) 1.55

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer (2009) 1.54

Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer (2010) 1.54

Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett (2008) 1.53

Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One (2012) 1.53

Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol (2011) 1.52

Articles by these authors

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55

Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med (2004) 30.26

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med (2011) 24.32

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93

Hepatocellular carcinoma. Lancet (2003) 22.54

Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 19.58

Hepatocellular carcinoma. Lancet (2012) 18.09

Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 16.21

IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell (2004) 15.82

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet (2002) 12.16

Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med (2011) 11.93

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology (2003) 11.55

Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med (2009) 10.21

Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med (2014) 9.94

Treatment of HCV infection by targeting microRNA. N Engl J Med (2013) 9.91

Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20

Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med (2014) 8.13

Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA (2012) 7.62

Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol (2004) 7.41

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer (2010) 7.25

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med (2005) 7.18

Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol (2006) 7.05

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol (2006) 6.95

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet (2012) 6.93

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol (2009) 6.86

Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology (2008) 6.75

Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol (2014) 6.64

Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo. Gastroenterology (2004) 6.60

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol (2005) 6.38

Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology (2008) 6.35

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31

Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med (2005) 6.22

Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology (2007) 6.12

Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med (2007) 6.11

Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol (2007) 6.08

Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93

Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology (2013) 5.88

Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis (2010) 5.85

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med (2007) 5.83

Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology (2007) 5.53

Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res (2007) 5.40

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int (2008) 5.25

Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol (2008) 5.24

Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol (2006) 5.17

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol (2004) 5.12

Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology (2003) 5.11

Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology (2008) 5.07

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol (2009) 5.05

Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology (2013) 5.05

Colorectal cancer. Lancet (2005) 4.90

Real-time elastography for noninvasive assessment of liver fibrosis in chronic viral hepatitis. AJR Am J Roentgenol (2007) 4.70

Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology (2008) 4.53

Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis (2005) 4.51

A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. Am J Respir Crit Care Med (2009) 4.51

Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50

TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity (2004) 4.48

SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology (2007) 4.44

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol (2007) 4.29

Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study. J Hepatol (2013) 4.28

A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology (2008) 4.23

miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A (2009) 4.15

Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. Gastroenterology (2007) 4.09

Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03

Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science (2002) 3.91

Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol (2009) 3.89

Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology (2009) 3.89

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol (2012) 3.88

Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology (2007) 3.85

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology (2008) 3.82

Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J Clin Invest (2003) 3.73

Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med (2007) 3.72